The National Institute for Health and Care Excellence11h
Record number of positive recommendations for blood cancer treatments
Around 5,000 blood cancer patients could benefit from 13 treatments recommended by NICE in 2024. This is the largest number of positive recommendations in a single year for blood cancer treatments.
The National Institute for Health and Care Excellence13h
First-ever NHS treatment approved for advanced Hodgkin lymphoma
From today, adults with advanced Hodgkin lymphoma have access to a new treatment, after we recommended brentuximab vedotin (brand name Adcetris) in combination with other therapies for routine NHS use ...
The National Institute for Health and Care Excellence1d
HST routing criteria: encouraging innovation in the treatment of ultra-rare diseases
Our chief medical officer, Professor Jonathan Benger, explains the crucial role the HST programme plays in encouraging ...
National Institute for Health and Care Excellence1d
Technology appraisal committee meeting (committee A)
The meeting will take place via Zoom, a secure web conferencing tool. The meeting will run from 9:00am to 2:45pm, although this may be subject to change. Joining links and times for each ...
National Institute for Health and Care Excellence5d
2 Information about blinatumomab
Blinatumomab (Blincyto, Amgen) is indicated for 'the treatment of adult patients with Philadelphia chromosome negative CD19-positive B-cell precursor leukaemia ALL in the consolidation phase'. The ...
National Institute for Health and Care Excellence7d
Individual research recommendation details
Psychological interventions:- Are the psychological interventions [cognitive behavioural therapy] (CBT), hypnotherapy and psychological therapy all equally effective in the management of [Irritable ...
National Institute for Health and Care Excellence7d
Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over
Fenfluramine is recommended as an option for treating seizures associated with Lennox–Gastaut syndrome (LGS), as an add-on to other antiseizure medicines, for people 2 years and over. It is ...
National Institute for Health and Care Excellence7d
Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over
There is a simple discount patient access scheme for fenfluramine. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence7d
2 Information about lisocabtagene maraleucel
Lisocabtagene maraleucel (liso‑cel; Breyanzi, Bristol-Myers Squibb) is indicated for 'the treatment of adult patients with diffuse large B‑cell lymphoma (DLBCL), high grade B‑cell lymphoma (HGBCL), ...
National Institute for Health and Care Excellence7d
5 Evaluation committee members and NICE project team
This topic was evaluated as a single technology evaluation by the highly specialised technologies evaluation committee. The highly specialised technologies evaluation committee and the 4 technology ...
National Institute for Health and Care Excellence7d
Resource impact summary report
This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...
National Institute for Health and Care Excellence7d
Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over
Fenfluramine (Fintepla, UCB) is indicated for 'the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) as an add-on therapy to other antiepileptic medicines for patients 2 years of age ...